TMU454 is a prototype GalNAc-PROTAC conjugate. TMU454 binds to ASGPR on the membrane of cells, and then is internalized via ASGPR-mediated endocytosis. TMU454 selectively degrades BRD4. TMU454 exhibits anticancer activity against hepatocellular carcinoma[1].